Home › Kanser sa Ovary › Oklahoma › Oklahoma City
Pag-aaral pangklinika para sa Kanser sa Ovary sa Oklahoma City, OK
Isang pag-aaral para sa Kanser sa Ovary ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Oklahoma City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Nagre-recruitPhase 1/2
- OU Health, Stephenson Cancer Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- University of Oklahoma, Oklahoma City
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Nagre-recruitPhase 2
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Nagre-recruitPhase 1/2
- Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- University of Oklahoma, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Nagre-recruitPhase 1/2
- OU Health Stephenson Cancer Center, Oklahoma City
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Nagre-recruitPhase 3
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Nagre-recruitPhase 1
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Nagre-recruitPhase 1
- Normunity Investigational Site, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Nagre-recruit
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- University of Oklahoma - Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Stephenson Cancer Center, Oklahoma City
Clinical Pre-screening Protocol for Ovarian Cancer
Nagre-recruitObservasyonal na pag-aaral
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Nagre-recruitPhase 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Nagre-recruitPhase 2
- University of Oklahoma, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Nagre-recruitPhase 1
- Stephenson Cancer Center, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Nagre-recruitPhase 1
- Dren Investigational Site, Oklahoma City
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Nagre-recruitPhase 2
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #13, Oklahoma City
Pag-aaral para sa Kanser sa Ovary sa ibang lungsod
- Houston, TX89 pag-aaral
- New York City, NY70 pag-aaral
- Boston, MA61 pag-aaral
- Los Angeles, CA50 pag-aaral
- Nashville, TN49 pag-aaral
- Arlington, VA46 pag-aaral
- Philadelphia, PA45 pag-aaral
- Columbus, OH39 pag-aaral
- St. Louis, MO38 pag-aaral
- Chicago, IL36 pag-aaral
- Pittsburgh, PA31 pag-aaral
- San Antonio, TX31 pag-aaral
Iba pang pag-aaral sa Oklahoma City
- Non-Small Cell Lung Cancer28 pag-aaral
- Kanser ng Endometrium25 pag-aaral
- Colorectal Cancer22 pag-aaral
- Kanser sa Prostate21 pag-aaral
- Kanser sa Baga19 pag-aaral
- Kanser sa Suso17 pag-aaral
- Metastatic Cancer16 pag-aaral
- Acute Myeloid Leukemia14 pag-aaral
- Kanser (lahat ng uri)14 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg13 pag-aaral
- Kanser sa Pancreas11 pag-aaral
- Kanser sa Pantog11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 7, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.